• This is a Healthcare Effectiveness & Data Information Set (HEDIS®) hybrid measure and includes all Medicaid beneficiaries.
• The annual reported rate captures activity during the stated measurement year (MY).
• In MY22, the Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) (HPC-AD) measure was modified by the measure steward into a combined measure that has two rates: HbA1C Control (<8%) and HbA1C Poor Control (>9%). The combined measure is called Hemoglobin A1c Control for Patients With Diabetes (HBD-AD).

The Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of NCQA.

This measure assesses the percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:

• HbA1c control (<8.0%).
• HbA1c poor control (>9.0%).

Diabetes is one of the most costly and highly prevalent chronic diseases in the United States. Diabetes is the seventh leading cause of death in the U.S. and killed approximately 84,000 people in 2018. Many complications such as heart disease, stroke, blindness, kidney failure and amputation can be prevented if diabetes is detected and addressed in the early stages. Controlling A1c blood levels helps reduce the risk of microvascular complications (eye, kidney and nerve diseases).

Last updated:  January 2024